Key Points
- Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells.
- Pevonedistat reduces disease burden in MPN mouse models.
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
Abstract